G3BP2

Across TCGA pan-cancer cohorts, G3BP2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated G3BP2 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher G3BP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated G3BP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, THYM, and KIRC are the cancer types where G3BP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.137	0.700	<.001	48	view →
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
KIRC	OS	Median	All	0.152	0.874	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.951	0.829	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

G3BP2–SCLC (OS)

Open the SCLC breakdown →